Publications by authors named "Evzen Gregora"

Claim this Profile
C
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Evzen Gregora

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Roman Hájek, Jiri Jarkovsky, Vladimír Maisnar, Ludek Pour, Ivan Špička, Evžen Gregora

Clin Lymphoma Myeloma Leuk· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.
Tomáš Jelínek, Vladimír Maisnar, Luděk Pour, Ivan Špička, Jiří Minařík, Evžen Gregora

Curr Med Res Opin· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Aneta Mikulasova, Christopher P Wardell, Alexander Murison, Eileen M Boyle, Graham H Jackson, Evzen Gregora

Haematologica· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).
Hauke Thomsen, Chiara Campo, Niels Weinhold, Miguel Inacio da Silva Filho, Luděk Pour, Evžen Gregora

Eur J Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Viera Sandecká, Roman Hájek, Luděk Pour, Ivan Špička, Vlastimil Ščudla, Evžen Gregora

Eur J Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
Aneta Mikulasova, Jan Smetana, Marketa Wayhelova, Helena Janyskova, Viera Sandecka, Evzen Gregora

Eur J Haematol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Jiri Minarik, Petr Pavlicek, Ludek Pour, Tomas Pika, Vladimir Maisnar, Evzen Gregora

PLoS One· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Jakub Radocha, Luděk Pour, Tomáš Pika, Vladimír Maisnar, Ivan Špička, Evžen Gregora

Eur J Haematol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Jiri Minarik, Viera Sandecka, Vladimir Maisnar, Evzen Gregora, Ivan Spicka

Leuk Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Pavel Nemec, Zuzana Zemanova, Petr Kuglik, Kyra Michalova, Jana Tajtlova, Evzen Gregora

Leuk Lymphoma· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Marta Krejci, Evzen Gregora, Jan Straub, Jiri Minarik, Vlastimil Scudla

Ann Hematol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Pavel Nemec, Zuzana Zemanova, Henrieta Greslikova, Kyra Michalova, Hana Filkova, Evzen Gregora

Biol Blood Marrow Transplant· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis